["SHIP2 and insulin signaling: what is its role in the pathogenesis and treatment of type 2 diabetes?"].
Based on the analysis of SHIP2+/- and SHIP2-/- mice showing that the lipid phophatase SHIP2 is an important negative regulator of the insulin pathway, we have suggested that the enzyme is a candidate gene for genetic predisposition to type 2 diabetes, and a potential therapeutic target for the same disease. Two years after, we propose to review these hypothesis in light of recent results from our laboratory, from international collaborations and from competitors in the field.
Schurmans
S
S
D000818:Animals; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000209:etiology*; D006801:Humans; D007328:Insulin / Q000502:physiology*; D000072183:Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases; D010744:Phosphoric Monoester Hydrolases / Q000502:physiology*
D007328:Insulin; D010744:Phosphoric Monoester Hydrolases; C098706:INPPL1 protein, human; D000072183:Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases